Asker Healthcare (ASKER) Fair Value & Analysis
Healthcare · SE · Market cap 30.4B SEK (≈ $3.2B) · ISIN SE0024171458
What is Asker Healthcare really worth?
A solid business, but trading 158% above our fair value of kr 28.26.
Strengths
Risks
For context
Fair value as of: Aug 27, 2026
From 24 valuation models · updated 9 days ago
Share price −10.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 35.32). The favourable scenario is already priced in.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (kr 16.49 to kr 35.32) leaves room in how you read the outcome.
Price vs Fair Value (17 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
17‑month range kr 59.16 – kr 130.59 · fair‑value band kr 16.49 – kr 35.32 · the kr 73.00 price screens above the kr 28.26 fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Asker Healthcare (ASKER) currently trades at kr 73.00, while our model-based Fair Value estimate is kr 28.26, implying the stock looks roughly 158.3% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 35.36 per share, and 0 of the 24 models we run sit above the kr 73.00 price. Bear case: the Asset-Based group reads lowest at kr 11.47, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Asker Healthcare generated revenue of 17.3B SEK at a net margin of 3.4%. Revenue grew 13.2% year over year. It earns a return on equity of 9.3%. Net debt stands at 4.9B SEK. Fundamentals as of Aug 27, 2026
Our scenario range runs from kr 16.49 (bear case) to kr 35.32 (bull case); at kr 73.00, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 44% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 36% fair-value upside, at −61%, ASKER screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly kr 0.7950 per share, which is 2.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (kr 35.36) versus Asset-Based (kr 11.47). Highest evidence: EPV (74).
Notify me when ASKER reaches fair value
Put ASKER on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care.
Full company description
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, it develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; and products for physiotherapy practices, as well as supplies exercise and treatment equipment and measurement. Additionally, it sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. Asker Healthcare Group AB (publ) was founded in 2006 and is headquartered in Danderyd, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Asker Healthcare reported revenue of 16.8B SEK in FY2025 versus 9.4B SEK in FY2021, a compound +15.7%/yr. Reported net income was 492M SEK in FY2025, compounding +1.3%/yr from FY2021.
ASKER screens 158% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 78 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $906.77 | $819.31 | −10% |
| Cencora, Inc COR | $330.97 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | −19% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | −24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| China National Medicines Corporation 600511 | ¥26.84 | ¥58.22 | +117% |
Compare Asker Healthcare with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Asker Healthcare (ASKER) overvalued or undervalued?
What is the fair value of ASKER?
What is the quality score of ASKER?
What is the revenue of Asker Healthcare (ASKER)?
What is the net profit margin of ASKER?
Does Asker Healthcare pay a dividend?
Watch Asker Healthcare in the live analysis
One click puts Asker Healthcare on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.